A stockholder’s recently unsealed complaint lays out the “disturbing details” surrounding the collapse of blood diagnostics company Theranos Inc., accusing its chief executive and former president of committing securities fraud and intentionally misleading investors into funding a now-abandoned business model.
Filed Oct. 10 in the Delaware Court of Chancery, the 66-page document was unsealed days later. In it, San Francisco-based Partner Fund Management accuses Theranos of making “misrepresentations, misleading statements, and material omissions about, among other things, the company’s technology, methods, regulatory interactions, and business plan.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
